Hi Phylogica,
In the March 2012 video briefing, Dr. Paul Watt highlighted that many antibody companies and scaffold companies are displaying diversity within one structural theme. Is this one of the things that distinguishes Phylogica from other companies operating in and targeting the 'undruggable' space? If so, are you able to elaborate on this point please?
Thank you.
Tony
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.29 |
Change
0.045(3.63%) |
Mkt cap ! $749.4M | |||
| Open | High | Low | Value | Volume |
| $1.25 | $1.29 | $1.25 | $337.0K | 265.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.29 | 58344 | 1 |
View Market Depth
| Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
| PYC (ASX) Chart |